

4P-Pharma joins forces with Qingdao Marine Biomedical Research Institute for translation research in China and Europe

法国 4P-Pharma 与中国青岛海洋生物医药研究院在中国和欧洲建立基础研究转化合作关系



Lille (France), 16th September 2021 – 4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules.

Mr. Daowen Du, European director of International Committee for the Promotion of Chinese Industrial Cooperatives ("Gung Ho International Committee" or "ICIC"), and Mr. Yu Wang, representative of 4P-Pharma in China, celebrating the signature of the MOU between QMBRI and 4P-Pharma in Qingdao (China).

2021年9月16日法国里尔。法国 4P-Pharma 和中国青岛海洋生物医药研究院 (QMBRI) 决定联合并发挥各自的专业领域，通过签署双方合作谅解备忘录 (MoU)，共同开发中国和欧洲的创新候选药物。

4P-Pharma, a French clinical-stage biotechnology company and the Qingdao Marine Biomedical Research Institute (QMBRI), a state protected institution located at Qingdao (China), announced today that they entered into a research collaboration in order to jointly develop new drug candidates in Europe and China.

4P-Pharma is specialized in the sourcing and acceleration of early-stage therapeutic molecules development to the clinic. QMBRI is a research institute focusing on the research and development of marine medicine, marine-derived traditional Chinese medicine and marine biological products through its exceptional computational analytics platforms that integrates iterative big data and in silico technologies (i.e. Computer-Aided Drug design, Quantitative Structure Activity Relationship, QSAR).

Part of this agreement, in the form of a Memorandum of Understanding (MoU), QMBRI will present 11 innovative early-stage drug candidates from its own research to 4P-Pharma's team. The objective will be to select and accelerate the development of drug candidates with high therapeutic potential for unmet medical needs through a R&D maturation program established by

4P-Pharma and jointly agreed upon. QMBRI and 4P-Pharma will together advance the lead candidates to the clinic in Europe and China.

QMBRI collaborates with the most prestigious research centers in China. As such, 4P-Pharma will benefit from additional Chinese opportunities in drug repurposing for European development through its partnership with QMBRI.

Under the MoU, 4P-Pharma will also present drug candidates from its sourcing activities to QMBRI after internal evaluation and validation. Thus, QMBRI will bring its expertise for the development of 4P-Pharma's lead candidates in China.

As such, QMBRI will contribute to the clinical development of 4P004, a disease-modifying osteoarthritis drug (DMOAD), in China. 4P004 has recently been incorporated into 4Moving Biotech, a spin-off company of 4P-Pharma dedicated to its clinical development. A mutual scientific committee, under the first Chairmanship of Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of the INSERM UMR-S938 research team, will oversee the human clinical development of 4P004 in Europe and China.

4P Pharma is supported by the French Law Firm DS Avocats for the legal aspects of its development in China.

"We are particularly impressed by 4P-Pharma's successful background, French and European partners", said Dali Zhang, Vice-President of QMBRI. "It is our ambition to create a fruitful and long-term partnership for our two countries and patients worldwide."

"We are very pleased to build this partnership with QMBRI's team. This public-private partnership demonstrates our shared commitment to develop breakthrough and novel therapies for patients", added Revital Rattenbach, Chairwoman of 4P-Pharma and 4Moving Biotech. "We strongly believe that our combining work will definitely benefit to Chinese, European and worldwide patients."

"As European director of International Committee for the Promotion of Chinese Industrial Cooperative (ICCIC, Gung Ho International Committee), I am especially happy of QMBRI and 4P-Pharma's partnership", completed Daowen Du, European director of ICCIC-Gung Ho. "The possibility to provide a quick access of repositioning drugs, whose benefit/risk ratio has been positively proved, to the largest number of people is particularly important for China. We welcome very strongly 4P-Pharma's expertise to guarantee Chinese drug candidates' arrival in Europe".

About Qingdao Marine Biomedical Research Institute (QMBRI)

Qingdao Marine Biomedical Research Institute (QMBRI), is an independent institution founded in 2014, focusing on the research and development of marine medicine, marine-derived traditional Chinese medicine and marine biological products. QMBRI is located in the beautiful coastal city of Qingdao, the center for marine research in China, on Fushan campus of Ocean University of China. Led by Professor Huashi Guan, a distinguished Professor in marine medicine and an academicien of the Chinese Academy of Engineering, QMBRI's mission is to accelerate the transform and incubation of new technologies and new products in the marine biomedical area, and to support the development of marine biomedical industry in a sustainable manner. The core team includes many distinguished leaders in their fields, including academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering, a number of recipients of the National Science Fund for Distinguished Young Scholars, Yangtze River Scholars and the Experts of National Thousand Talent Program of China. QMBRI has spent great effort to enhance and upgrade its research and development facilities and equipment with modern technologies and international standards, with supports from local governments. With its drug discovery and development platform based on computational analytics that integrates iterative big data and in silico technologies (i.e. Computer-Aided Drug design, Quantitative Structure Activity), exceptional research teams, QMBRI aims to find new therapy concepts for diseases with high unmet medical needs, offering the most efficient matching of clinical indications and drug candidate and state of the art technologies. Its objectives are to build the largest blue biomarine bank in the world.

<http://en.qdmbri.com/>

About 4P-Pharma

4P-Pharma is a French clinical-stage biotechnology company, located at the Institut Pasteur de Lille, specialized in the sourcing and acceleration of early-stage therapeutic molecules addressing unmet medical needs. 4P-Pharma aims to detect the most promising innovations from partners (i.e. academic institutions, biotech companies and TTOs) and performs in-house technological due-diligence applying stringent industry criteria. 4P-Pharma gathers all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision to bring innovations to clinical phases. Since the foundation of 4P-Pharma, in 2014, more than 300 molecules have been pre-evaluated, a technological due diligence has been carried out on 18 of them. Two are now incorporated in clinical-stage asset centric companies owned by 4P-Pharma.

www.4p-pharma.com

www.linkedin.com/company/4p-pharma

@4P_Pharma

About 4P004

4P004 is a disease modifying drug for the treatment of Osteoarthritis (OA), developed by 4Moving Biotech. It is an already approved incretin mimetic (a Glucagon-Like Peptide-1 receptor agonist) formulated for intra-articular administration. OA is a chronic degenerative disease characterized by chronic joint pain and functional impairment, affecting 15% of the adult worldwide population. 4P004 has the potential to stop and reverse the course of the disease improving patient's quality of life through its unique triple effect: anti-inflammatory, analgesic and cartilage regeneration, thus qualifying as a Disease Modifying OA Drug. Protected by two international patents, it has undergone extensive preclinical validation and will move towards clinical phases in 2021.

About 4Moving Biotech

4Moving Biotech is a biotech start-up company focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). It addresses the high unmet medical need for a curative treatment against osteoarthritis (OA), a chronic degenerative joint disease.

4Moving Biotech was established in July 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Institut Pasteur de Lille (France).

4Moving Biotech is headed by Revital Rattenbach, PhD, MBA, founder and chairwoman of 4P-Pharma, as Chairwoman, and Prof. Francis Berenbaum, Head of Rheumatology department at St-Antoine's hospital in Paris (AP-HP), as CEO/CMO.

<https://4p-pharma.com/our-pipeline/pipeline-inflammation/>

<https://www.linkedin.com/company/4moving-biotech/>

@4Moving_Biotech

QMBRI press contact

Xiaole Zhang, Vice-President Assistant

Phone: +86 0532 85906858

E-mail: qinqinle@163.com

4P-Pharma and 4Moving Biotech press contact

Roselina Lam, Business Development and Licensing Manager

Phone: +33 (0)1 44 97 40 59 – E-mail: roselina@4p-pharma.com